Clinical Trials Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2017; 23(14): 2601-2612
Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2601
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder
Zheng-Chun Wu, Li Xiong, Ling-Xiang Wang, Xiong-Ying Miao, Zi-Ru Liu, Dai-Qiang Li, Qiong Zou, Kui-Jie Liu, Hua Zhao, Zhu-Lin Yang
Zheng-Chun Wu, Li Xiong, Ling-Xiang Wang, Xiong-Ying Miao, Zi-Ru Liu, Kui-Jie Liu, Hua Zhao, Zhu-Lin Yang, General Surgery Department, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Zheng-Chun Wu, Li Xiong, Ling-Xiang Wang, Xiong-Ying Miao, Zi-Ru Liu, Kui-Jie Liu, Hua Zhao, Zhu-Lin Yang, Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Dai-Qiang Li, Department of Pathology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Qiong Zou, Department of Pathology, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China
Author contributions: Wu ZC, Xiong L and Wang LX carried out studies and wrote the paper; Yang ZL designed the study and revised the paper; Liu ZR, Liu KJ and Yang ZL performed the statistical analysis; Miao XY and Zhao H conceived of the study and participated in the design and coordination; Li DQ and Zou Q collected specimens and experimental materials; Wu ZC and Xiong L contributed equally to this work.
Supported by the National Natural Science Foundation of China, No. 81372628 and No. 81402536; the Changsha Science and Technology Plan, No. K1205018-31.
Institutional review board statement: This study was approved by the Institutional Review Board of Second Xiangya Hospital, Central South University.
Clinical trial registration statement: This registration policy applies to prospective, randomized, controlled trials only.
Informed consent statement: This study is exempt from informed consent since it is a retrospective study and the data collection and analysis were carried out without disclosing patients’ identities.
Conflict-of-interest statement: All authors declare that there are no commercial, personal or any other potential conflicting interests related to the submitted manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Zhu-Lin Yang, Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, 139 Middle Renmin Rd., Changsha 410011, Hunan Province, China. 4896142@qq.com
Telephone: +86-731-88187376 Fax: +86-731-84898168
Received: November 29, 2016
Peer-review started: November 30, 2016
First decision: December 28, 2016
Revised: February 1, 2017
Accepted: March 2, 2017
Article in press: March 2, 2017
Published online: April 14, 2017
Processing time: 135 Days and 19.8 Hours
Core Tip

Core tip: Gallbladder carcinoma (GBC) is a highly aggressive malignancy of the biliary tract. However, biological markers for the diagnosis, prognosis, and targeted therapy of GBCs are still not clear. In this study, we investigated the clinicopathological significance of ROR2 and WNT5a in squamous/adenosquamous carcinoma (SC/ASC) and adenocarcinoma (AC) of the gallbladder. We found that positive ROR2 or WNT5a expression in both SC/ASC or AC patients were negatively correlated with postoperative survival rate and positively correlated with mortality. Elevated expression levels of ROR2 or WNT5a are associated with a higher risk of GBC and are independent prognostic predictors.